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inhibit the expression of HBsAg, HBeAg, and HBV DNA replication
in vitro in a dose-dependent manner. A RT-PCR analysis indicated
that the expression of cccDNA changed signiﬁcantly in the MP
treatment group compared to the control group and in a dose
and time-dependent manner. FK506 did not the same role in
the levels of HBVDNA and cccDNA. However, FK506 at different
nontoxic contrations showed no signiﬁcant inhibitory effect on
the levels of HBsAg HBeAg and HBVDNA.
Conclusion: Our study identiﬁed MP does- and time-dependently
inhibits the HBV replication in vitro, and found that cccDNA for
this inhibitory effect. FK506 does not exercise similar effects.
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Objectives: Notch receptors are implicated in modulating the
differentiation of antigen speciﬁc T cells to regulatory T cells.
TGF-β as a key mediator, acts synergistically with regulatory
cells. Our objective was to study the expression of Notch 1,FOXP3
and TGF-β signaling in PBMCs, liver inﬁltrated lymphocytes in pa-
tients with HBV infection.
Methods: Patients with chronic hepatitis B (CHB) (n=10) (age
29.4±13.2 yr., M:F=8:2), HBV cirrhosis (n=8) (age-45.6±12 yr.
M:F=2:1) and liver biopsies from normal liver (n=8) (age 49±3.8
yr. M:F=3:1) were studied. PBMCs and LIL were isolated from
blood and liver tissues. Percentages of regulatory T cells with
Notch expression were analyzed by FACS Analysis. mRNA expres-
sion of Notch1, HES1, Jagged1, TGF-β, STAT1, SMAD3 and SMAD4
genes was analyzed by quantitative RT-PCR in PBMCs, LIL and
biopsies.
Results: There was a signiﬁcantly higher co-expression of Notch1
and the percentages of NOTCH1/FOXP3 (50.4% vs.3.72 and 2%)
(p=0.05) in liver inﬁltrated lymphocytes of cirrhotic patients than
peripheral blood. Expression of TGF-β, STAT1, SMAD3 and SMAD4
in cirrhotic LIL was signiﬁcantly 2-3 folds lower than PBMCs. In
chronic HBV biopsies, expression of TGF-β, STAT1, SMAD3 and
SMAD4 was 4-6 folds higher than in normal liver biopsies.
Conclusion: We showed that higher expression of Notch1 and
FOXP3 expression in liver inﬁltrated lymphocytes may have
differentiated induced regulatory T cells. However, decreased
expression of TGF-β and its downstream signaling molecules in
LILs may be responsible for loss of its regulatory cells suppressive
ability.
PP-064 A tenofovir therapy HBV mathematical model for
HBeAg negative and positive patient
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Background: HBeAg negative and HBeAg positive patients are
different in the HBV replication rate. Based on P.Marcellin et al’s
clinical data and the HBV infection dynamic model proposed by
Nowak et al. we set up a Tenofovir therapy model for HBeAg
negative and positive, which have good agreement with above
clinical data.
Methods: A model of HBV is described by four variables: x, y,
v, z represent uninfected cells, infected cells, free virus, and
immune cells. The model include 10 parameters: λ, d, b, a, p, k,
u, k2, k3, k4 where the meanings of λ, d, b, a, p, k, u are the
same as those given in Nowak’s model, k2 represents the curative
effect, k3, k4 are relevant to the immune, we choose {λ, d, b,
a, p, u, k3, k4 = 4.621e5, 6.9e-3, 6.508e-4, 6.9e-3, 0.058, 0.35,
0.95, 0.036}
For HBeAg positive and negative, we chose k=5, k2=4.85, and k=2,
k2=1.98 respectively, which reﬂect the different HBV replication
rate between HBeAg positive and negative patient.
Results: The simulation data of our model are qualitatively
agreement with the HBeAg positive and negative clinical data
during the treatment with Tenofovir.
Conclusion: The discrepancy between HBeAg negative and posi-
tive were reﬂected through different parameters by our model,
which shows our model may possibly capture the dynamics of
anti-HBV infection treatment with Tenofovir.
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Objective: To evaluate the efﬁcacy and safety of different
dosage of Ademetionine (Transmetil) in different cholestasis
diseases.
Methods: It’s a retrospective study, 56 cases who treated with
Ademetionine (Transmetil) were assigned to 1g/d and 2g/d by
the dosage they used. There is no statistic difference between
the two groups in age, height, body weight, heart rate, blood
pressure and sex ratio (P>0.05). The levels of ALT, AST, TBiL,
DBiL, GGT and TBA before treated and 2 weeks after treated of
both groups were observed.
Results: After 2 wk of treatment, the levels of ALT, AST, TBiL,
DBiL, GGT and TBA were reduced signiﬁcantly (p=0.001, 0.002,
0.029, 0.01, 0.002, 0.002 P<0.05) compared with those before
treatment, but the reduced levels of ALT, AST and GGT had no
marked difference between the two groups (p=0.055, 0.14, 0.774
P>0.05). And the reduced levels of TBiL, DBiL and TBA were
signiﬁcantly different between the two groups (p=0.025, 0.038,
0.039 P<0.05). No severe adverse reactions were found in both
groups.
Conclusions: Ademetionine (Transmetil) has obvious effect on
Cholestasis diseases, and the treatment of dosage 2g/d has more
effective in reduce TBiL, DBiL and TBA than that of 1g/d. It’s
safe in both dosage groups.
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Background:To study the effect of adeforvir dipivoxil on HBcAg-
speciﬁc cytotoxic T cells in patients with chronic hepatitis B
(CHB).
Methods: Frequency of circulating HBcAg-speciﬁc cytotoxic T
cells from 11 HLA-A2+ patients with chronic hepatitis B were
studied longitudinally before and after adeforvir dipivoxil ther-
apy by HLA-A2/peptide tetramer staining.
Results: Frequencies of HBcAg-speciﬁc cytotoxic T cells were
no signiﬁcant differences between before and after adeforvir
dipivoxil therapy.
Conclusion: There is probably no effect effect of adeforvir
dipivoxil on HBcAg-speciﬁc cytotoxic T cells in patients with CHB.
PP-067 Effects of interventional therapy for primary liver
carcinoma on the liver function of patients
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Background: The effects of interventional therapy for hepato-
